PROCEPT BioRobotics Corporation PRCT
20.62 USD +0.35 (+1.73%)
At closeNov 6, 2026, 5:23 PM EST
20.62 0.00 0.00%
After hours · Nov 6, 5:23 PM ET
19.41 Day range 20.80
16.67 52-week range 38.11
- YTD
- -34.46%
- 1 year
- -34.12%
- Market cap
- 1.19B
- Revenue (ttm)
- 352.30M
- Profit margin
- -32.60%
- EPS (ttm)
- -2.02
- Shares out
- 57.54M
- Forward P/E
- -17.60
- YTD return
- -34.46%
- 1-year return
- -34.12%
- Volume
- 1.71M
- Avg volume
- 1.26M
- Open
- 20.14
- Previous close
- 20.27
- Day's range
- 19.41 – 20.80
- 52-week range
- 16.67 – 38.11
- Beta
- 0.84
- Analysts
- Hold
- Price target
- 22.25 (+7.9%)
- Earnings date
- Feb 24, 2027
5D +1.00 (+5.10%)
Key statistics
- Enterprise value
- 1.02B
- PEG ratio
- 0.00
- Price / sales
- 3.37
- Price / book
- 3.60
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 18.00%
- Free cash flow
- -44.44M
- Total cash
- 218.37M
- Total debt
- 76.99M
- Return on equity
- -32.39%
- Short % of float
- 13.44%
- 50-day average
- 19.32
- 200-day average
- 23.12
Analyst view
Consensus: hold
Hold
Price target (mean) 22.25 +7.9% upside
Now 20.62
- Target (low)
- 16.00
- Target (mean)
- 22.25
- Target (high)
- 30.00
Ratings (0m) 15 5 buy · 9 hold · 1 sell
- Strong buy2
- Buy3
- Hold9
- Sell0
- Strong sell1
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate -0.25497.
Financials — quick view
PRCT Revenue — quarterly 94.50M
PRCT Net income — quarterly -26.86M
PRCT EPS — quarterly -0.47
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 30, 2026 | -0.25 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -0.39152 | -0.46 | -0.07 | -17.49% |
| Aug 4, 2026 | Jun 30, 2026 | -0.46186 | -0.47 | -0.01 | -1.76% |
| Apr 29, 2026 | Mar 31, 2026 | -0.55 | -0.56 | -0.01 | -1.82% |
| Feb 25, 2026 | Dec 31, 2025 | -0.32 | -0.53 | -0.21 | -65.62% |
| Nov 4, 2025 | Sep 30, 2025 | -0.41 | -0.38 | +0.03 | +7.32% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Truist Securities | main | Hold | Hold |
| Nov 5, 2026 | UBS | main | Neutral | Neutral |
| Nov 5, 2026 | Leerink Partners | main | Market Perform | Market Perform |
| Oct 7, 2026 | Barclays | init | — | Overweight |
| Aug 5, 2026 | TD Cowen | main | Buy | Buy |
| Aug 5, 2026 | Piper Sandler | main | Overweight | Overweight |
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- procept-biorobotics.com
News
Truist Securities Maintains Hold on PROCEPT BioRobotics, Raises Price Target to $24 
UBS Maintains Neutral on PROCEPT BioRobotics, Raises Price Target to $21 
Leerink Partners Maintains Market Perform on PROCEPT BioRobotics, Raises Price Target to $22 
PROCEPT BioRobotics Q3 Earnings Call Highlights 
PROCEPT BioRobotics Corporation (PRCT) Q3 2026 Earnings Call Transcript 
PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Lags Revenue Estimates 
PROCEPT BioRobotics Q3 2026 Earnings Call Transcript 
PROCEPT BioRobotics Affirms FY2026 Sales Guidance of $390.000M-$410.000M vs $395.409M Est 
PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance - Barclays Initiates Coverage On PROCEPT BioRobotics with Overweight Rating, Announces Price Target of $30
Your note
Sign in to keep a note on PRCT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DESAI ANTAL ROHIT | Director | Stock Award(Grant) | Jun 8, 2026 | 38,467 |
| HARRIS TAYLOR C | Director | Stock Award(Grant) | Jun 8, 2026 | 102,491 |
| MOLL FREDERIC H | Director | Stock Award(Grant) | Jun 8, 2026 | 866,474 |
| NOURI ALALEH | Officer | Sale | Sep 8, 2026 | 127,737 |
| SHARMA POOJA | Officer | Stock Award(Grant) | Aug 12, 2026 | 111,181 |
| SHIBLAQ HISHAM | Officer | Sale | Jun 5, 2025 | 63,133 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.46% | 4,869,828 | 100.42M | Jun 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 5.68% | 3,265,704 | 67.34M | Jun 29, 2026 |
| BNP Paribas Asset Management Holding S.A. | 4.91% | 2,823,849 | 58.23M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.39% | 2,526,802 | 52.10M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.28% | 2,460,802 | 50.74M | Jun 29, 2026 |
| State Street Corporation | 2.81% | 1,617,475 | 33.35M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.97% | 1,708,164 | 35.22M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.52% | 1,448,096 | 29.86M | Sep 29, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 2.29% | 1,318,120 | 27.18M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.15% | 1,239,150 | 25.55M | Jun 29, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Venture Fund | 1.86% | 1,072,227 | 22.11M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.24% | 711,299 | 14.67M | Jun 29, 2026 |